Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy
Introduction The determinants and mechanisms contributing to diabetic sensorimotor polyneuropathy (DSPN) remain unclear. Since neuroinflammation and altered nerve regeneration have been implicated in the pathogenesis of both DSPN and neuropathic pain, we hypothesized that the corresponding biomarker...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-05-01
|
| Series: | BMJ Open Diabetes Research & Care |
| Online Access: | https://drc.bmj.com/content/7/1/e000752.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846121612338790400 |
|---|---|
| author | Barbara Thorand Annette Peters Dan Ziegler Alexander Strom Gidon J Bönhof Julia M Kannenberg Margit Heier Wolfgang Rathmann Christina Meisinger Michael Roden Christian Herder |
| author_facet | Barbara Thorand Annette Peters Dan Ziegler Alexander Strom Gidon J Bönhof Julia M Kannenberg Margit Heier Wolfgang Rathmann Christina Meisinger Michael Roden Christian Herder |
| author_sort | Barbara Thorand |
| collection | DOAJ |
| description | Introduction The determinants and mechanisms contributing to diabetic sensorimotor polyneuropathy (DSPN) remain unclear. Since neuroinflammation and altered nerve regeneration have been implicated in the pathogenesis of both DSPN and neuropathic pain, we hypothesized that the corresponding biomarkers could be associated with DSPN in general and could have the potential to discriminate between the painful and painless DSPN entities.Methods In a cross-sectional study using multimarker proximity extension assay technology we assessed 71 serum biomarkers including cytokines, chemokines, growth factors, receptors, and others in patients with type 2 diabetes with DSPN (DSPN+) (n=304) or without DSPN (DSPN−) (n=158) and persons with normal glucose tolerance (NGT) without polyneuropathy (n=354).Results After adjustment for multiple testing and sex, age, body mass index, HbA1c, and smoking, the serum levels of 17 biomarkers (four cytokines, five chemokines, four growth factors, two receptors, two miscellaneous) were lower in DSPN+ than in DSPN− and NGT. In DSPN+, six of these biomarkers were associated with peripheral nerve function. The concentrations of 15 other biomarkers differed between NGT and both DSPN+ and DSPN−, but not between DSPN+ and DSPN−. No differences in biomarker levels were found between patients with painful (n=164) and painless DSPN (n=140).Conclusions Deficits in systemic cytokines, chemokines, and growth factors promoting nerve regeneration in patients with type 2 diabetes are linked to polyneuropathy in general but not specifically to the painful or painless entity.Trial registration number NCT02243475. |
| format | Article |
| id | doaj-art-e55e3963d5a54ce98e6c84f1efb77079 |
| institution | Kabale University |
| issn | 2052-4897 |
| language | English |
| publishDate | 2019-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Diabetes Research & Care |
| spelling | doaj-art-e55e3963d5a54ce98e6c84f1efb770792024-12-15T20:45:09ZengBMJ Publishing GroupBMJ Open Diabetes Research & Care2052-48972019-05-017110.1136/bmjdrc-2019-000752Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathyBarbara Thorand0Annette Peters1Dan Ziegler2Alexander Strom3Gidon J Bönhof4Julia M Kannenberg5Margit Heier6Wolfgang Rathmann7Christina Meisinger8Michael Roden9Christian Herder10Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany3 Institute of Epidemiology, Helmholtz Zentrum Munchen, German Research Center for Health and Environment, Neuherberg, GermanyInstitute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, GermanyInstitute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, GermanyInstitute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, GermanyInstitute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, GermanyInstitute of Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Neuherberg, GermanyGerman Center for Diabetes Research, Partner Düsseldorf, Neuherberg, GermanyIndependent Research Group Clinical Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, GermanyInstitute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany2German Diabetes Center, Düsseldorf, GermanyIntroduction The determinants and mechanisms contributing to diabetic sensorimotor polyneuropathy (DSPN) remain unclear. Since neuroinflammation and altered nerve regeneration have been implicated in the pathogenesis of both DSPN and neuropathic pain, we hypothesized that the corresponding biomarkers could be associated with DSPN in general and could have the potential to discriminate between the painful and painless DSPN entities.Methods In a cross-sectional study using multimarker proximity extension assay technology we assessed 71 serum biomarkers including cytokines, chemokines, growth factors, receptors, and others in patients with type 2 diabetes with DSPN (DSPN+) (n=304) or without DSPN (DSPN−) (n=158) and persons with normal glucose tolerance (NGT) without polyneuropathy (n=354).Results After adjustment for multiple testing and sex, age, body mass index, HbA1c, and smoking, the serum levels of 17 biomarkers (four cytokines, five chemokines, four growth factors, two receptors, two miscellaneous) were lower in DSPN+ than in DSPN− and NGT. In DSPN+, six of these biomarkers were associated with peripheral nerve function. The concentrations of 15 other biomarkers differed between NGT and both DSPN+ and DSPN−, but not between DSPN+ and DSPN−. No differences in biomarker levels were found between patients with painful (n=164) and painless DSPN (n=140).Conclusions Deficits in systemic cytokines, chemokines, and growth factors promoting nerve regeneration in patients with type 2 diabetes are linked to polyneuropathy in general but not specifically to the painful or painless entity.Trial registration number NCT02243475.https://drc.bmj.com/content/7/1/e000752.full |
| spellingShingle | Barbara Thorand Annette Peters Dan Ziegler Alexander Strom Gidon J Bönhof Julia M Kannenberg Margit Heier Wolfgang Rathmann Christina Meisinger Michael Roden Christian Herder Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy BMJ Open Diabetes Research & Care |
| title | Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy |
| title_full | Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy |
| title_fullStr | Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy |
| title_full_unstemmed | Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy |
| title_short | Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy |
| title_sort | deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy |
| url | https://drc.bmj.com/content/7/1/e000752.full |
| work_keys_str_mv | AT barbarathorand deficitsinsystemicbiomarkersofneuroinflammationandgrowthfactorspromotingnerveregenerationinpatientswithtype2diabetesandpolyneuropathy AT annettepeters deficitsinsystemicbiomarkersofneuroinflammationandgrowthfactorspromotingnerveregenerationinpatientswithtype2diabetesandpolyneuropathy AT danziegler deficitsinsystemicbiomarkersofneuroinflammationandgrowthfactorspromotingnerveregenerationinpatientswithtype2diabetesandpolyneuropathy AT alexanderstrom deficitsinsystemicbiomarkersofneuroinflammationandgrowthfactorspromotingnerveregenerationinpatientswithtype2diabetesandpolyneuropathy AT gidonjbonhof deficitsinsystemicbiomarkersofneuroinflammationandgrowthfactorspromotingnerveregenerationinpatientswithtype2diabetesandpolyneuropathy AT juliamkannenberg deficitsinsystemicbiomarkersofneuroinflammationandgrowthfactorspromotingnerveregenerationinpatientswithtype2diabetesandpolyneuropathy AT margitheier deficitsinsystemicbiomarkersofneuroinflammationandgrowthfactorspromotingnerveregenerationinpatientswithtype2diabetesandpolyneuropathy AT wolfgangrathmann deficitsinsystemicbiomarkersofneuroinflammationandgrowthfactorspromotingnerveregenerationinpatientswithtype2diabetesandpolyneuropathy AT christinameisinger deficitsinsystemicbiomarkersofneuroinflammationandgrowthfactorspromotingnerveregenerationinpatientswithtype2diabetesandpolyneuropathy AT michaelroden deficitsinsystemicbiomarkersofneuroinflammationandgrowthfactorspromotingnerveregenerationinpatientswithtype2diabetesandpolyneuropathy AT christianherder deficitsinsystemicbiomarkersofneuroinflammationandgrowthfactorspromotingnerveregenerationinpatientswithtype2diabetesandpolyneuropathy |